The Neuroprotective Effects of Piracetam on Cisplatin-Induced Cognitive Decline.
Elbeltagy MahaBann KhraisatLujain AlZoubiLeen HmoudAhmad AlJeadyMohammed YousefAhmed SalmanPublished in: The International journal of neuroscience (2023)
Should the outcomes of Piracetam observed in this investigation be applicable to patients, it might offer a relatively straightforward approach to mitigate the cognitive impacts endured by cancer survivors following exposure to chemotherapy. Future research will be needed to study Piracetam's effect on mice with brain cancer after Cisplatin treatment in order to extrapolate the results onto cancer patients.
Keyphrases
- cognitive decline
- end stage renal disease
- mild cognitive impairment
- ejection fraction
- newly diagnosed
- chronic kidney disease
- papillary thyroid
- young adults
- peritoneal dialysis
- prognostic factors
- childhood cancer
- white matter
- type diabetes
- locally advanced
- multiple sclerosis
- squamous cell carcinoma
- patient reported outcomes
- radiation therapy
- brain injury
- insulin resistance
- high fat diet induced
- functional connectivity
- rectal cancer
- smoking cessation